



DEPARTMENT OF HEALTH AND HUMAN SERVICES  
PUBLIC HEALTH SERVICE

**ESTABLISHMENT REGISTRATION AND LISTING FOR HUMAN CELLS, TISSUES,  
AND CELLULAR AND TISSUE-BASED PRODUCTS (HCT/Ps)**

(See reverse side for instructions)

**1. REGISTRATION NUMBER**  
(FDA Establishment Identifier)

FEI: 3005897621

2

**ADDITIONAL INFORMATION:**

- Proprietary Names:
- s. Amniotic Membrane: AmbioDisk, Ambio2, Ambio5, AmnioFix, AmnioRepair, AmnioShield, AmnioVantage, AmnioVo, BioXclude, EpiBurn, EpiFix, EpiXL, RDX2, OcuFix1, OcuFix2, Provenda
- t. Placenta: AmnioFill
- u. Umbilical Cord: AmnioCord, AmnioVantage, EpiCord, Provenda
- v. Amniotic Fluid: AmnioFlo, AmnioVantage, OrthoFlo

**Proprietary Name(s):**



April 12, 2017

To Whom It May Concern,

In regards to Form FDA 3356, the expiration date listed in the top corner (OMB No. 0910-0543) corresponds to an internal form expiration/review date that is for FDA Use Only. This date does not correspond with the expiration of a facility's registration with the FDA.

Despite the form's expiration date of 03/31/2017, MiMedx Tissue Services, LLC maintains a Registered/Active status with the FDA as a Tissue Bank (Registration Number 3005897621) and will continue to maintain this registration per FDA requirements.

The MiMedx registration is valid for one year post the FDA's validation date of 03/17/2017. Therefore, the posted FDA registration is valid through 03/17/2018.

Any additional registration inquiries may be made by contacting MiMedx Customer Service at [CustomerService@MiMedx.com](mailto:CustomerService@MiMedx.com) or 866-477-4219.

Thank you,

A handwritten signature in black ink that reads "J. Mark Rogers". The signature is fluid and cursive, with the first and last names being the most prominent.

J. Mark Rogers, CTBS  
VP, QA/RA  
Tissue Bank Director Designee

*Innovations In Regenerative Biomaterials*